Rheumatoid Arthritis Diagnostic Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End User, By Region & Competition, 2021-2031F

Description

The Global Rheumatoid Arthritis Diagnostic Tests Market is projected to expand from USD 3.31 Billion in 2025 to USD 4.72 Billion by 2031, registering a CAGR of 6.09%. This market encompasses laboratory assays and imaging technologies designed to detect autoimmune markers and assess joint inflammation, playing a critical role in confirming diagnoses and monitoring disease progression. Growth is largely fueled by the rising incidence of autoimmune conditions and an expanding geriatric population, alongside a clinical emphasis on early intervention to prevent irreversible joint damage. As reported by the Arthritis Foundation, approximately 1.3 million adults in the United States were affected by rheumatoid arthritis in 2025, highlighting the demand for effective screening tools.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 3.31 Billion
Market Size 2031	USD 4.72 Billion
CAGR 2026-2031	6.09%
Fastest Growing Segment	Serology Test
Largest Market	North America

The market faces significant hurdles, however, due to the high cost of sophisticated diagnostic instruments in developing nations. The expense associated with specialized assays and advanced imaging systems limits their widespread adoption in regions with constrained financial resources. This economic barrier is further compounded by the challenge of diagnosing patients who do not exhibit standard biomarkers, creating a substantial impediment to global market expansion. Consequently, the difficulty in implementing comprehensive testing in cost-sensitive areas remains a critical restraint for the industry.

Market Driver

A primary catalyst for the diagnostic tests market is the escalating global prevalence of rheumatoid arthritis, which drives the need for accurate and scalable screening methodologies. As autoimmune disorder rates climb, healthcare infrastructure faces increasing pressure to establish diagnostic frameworks capable of identifying the disease at its onset. This urgency is intensified by the severe health and economic consequences of delayed diagnosis within the working-age population. According to a June 2025 article in PLOS, there were 11.88 million rheumatoid arthritis cases among working-age individuals globally in 2021, underscoring the vital necessity for accessible serological and imaging tests to manage this growing patient cohort effectively.

Concurrently, the market is being transformed by breakthroughs in immunoassay technologies and the discovery of novel biomarkers, which enhance sensitivity and facilitate personalized care. The integration of artificial intelligence and machine learning with conventional diagnostics is enabling more accurate predictions of therapeutic responses and better clinical decision-making. For example, Scipher Medicine announced in June 2025 the validation of its AI-driven RA Response Calculator using data from nearly 1,500 patients to improve treatment evaluation. This technological momentum is supported by significant investments, such as Aqtual's receipt of $31 million in Series B funding in 2025 to commercialize its precision medicine solutions.

Market Challenge

The prohibitive cost of advanced diagnostic tools in developing economies represents a major obstacle to the expansion of the rheumatoid arthritis diagnostic tests market. Specialized assays and modern imaging equipment often carry price tags that exceed the budgetary limits of healthcare systems in these regions, forcing providers to depend on basic clinical assessments rather than precise screening methods. This disparity in affordability restricts the sales volume of advanced test kits, thereby limiting revenue growth in emerging markets where financial constraints are a dominant factor.

Furthermore, these economic limitations hinder the identification of patients who lack standard biomarkers, as the comprehensive testing required for such cases is frequently too expensive. The inability to scale operations in price-sensitive regions stalls market progress and prevents broader access to premium diagnostic solutions. Data from the International Society for Pharmacoeconomics and Outcomes Research in 2025 highlighted this issue, reporting that average annual direct costs for managing rheumatoid arthritis in low- and middle-income countries ranged between USD 523 and USD 2,838 per patient, emphasizing the severe financial barriers to widespread adoption.

Market Trends

The rise of Tele-Rheumatology and remote monitoring tools is shifting disease management from episodic clinical visits to continuous tracking via digital platforms. By leveraging smartphone applications to record real-time data on joint inflammation and symptom variability, these technologies enable timely treatment adjustments and offer clinicians objective, longitudinal insights. This evolution bridges the gap between daily patient life and medical supervision, enhancing care delivery. As noted by Medscape in March 2025, the DETECTRA mobile app achieved an 84% diagnostic accuracy in distinguishing swollen from non-swollen joints, demonstrating the potential of digital tools in decentralized healthcare settings.

Another significant trend is the development of novel biomarkers specifically targeting seronegative patients, addressing diagnostic voids for those who test negative for standard indicators like Rheumatoid Factor. Researchers are identifying alternative autoantibodies to confirm the disease in its seronegative form, which helps prevent treatment delays associated with inconclusive standard tests. According to an April 2025 article by AiArthritis, the anti-RA 33 biomarker was found in 42% of patients who subsequently developed seronegative rheumatoid arthritis. This advancement significantly improves screening capabilities for a subgroup that has historically been difficult to diagnose.

Key Market Players

Abbott Laboratories Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Exagen Inc.
Augurex Life Sciences Corp.
Danaher Corporation
Bio-Rad Laboratories, Inc.
Tulip Diagnostics (P) Ltd
Boditech Med Inc.
Getein Biotech, Inc.

Report Scope

In this report, the Global Rheumatoid Arthritis Diagnostic Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatoid Arthritis Diagnostic Tests Market, By Test Type

Serology Test
Monitoring RA Treatment Efficiency Tests

Rheumatoid Arthritis Diagnostic Tests Market, By End User

Diagnostic Laboratories
Private Laboratories
Public Laboratories
Ambulatory Surgical Centers

Rheumatoid Arthritis Diagnostic Tests Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatoid Arthritis Diagnostic Tests Market.

Available Customizations:

Global Rheumatoid Arthritis Diagnostic Tests Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatoid Arthritis Diagnostic Tests Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Test Type (Serology Test {Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests}, Monitoring RA Treatment Efficiency Tests {Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), Creatinine Test})
- 5.2.2. By End User (Diagnostic Laboratories, Private Laboratories, Public Laboratories, Ambulatory Surgical Centers)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Rheumatoid Arthritis Diagnostic Tests Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Test Type
- 6.2.2. By End User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Test Type
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Test Type
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Test Type
    - 6.3.3.2.2. By End User

7. Europe Rheumatoid Arthritis Diagnostic Tests Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Test Type
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Test Type
    - 7.3.1.2.2. By End User
- 7.3.2. France Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Test Type
    - 7.3.2.2.2. By End User
- 7.3.3. United Kingdom Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Test Type
    - 7.3.3.2.2. By End User
- 7.3.4. Italy Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Test Type
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Test Type
    - 7.3.5.2.2. By End User

8. Asia Pacific Rheumatoid Arthritis Diagnostic Tests Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Test Type
- 8.2.2. By End User
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Test Type
    - 8.3.1.2.2. By End User
- 8.3.2. India Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Test Type
    - 8.3.2.2.2. By End User
- 8.3.3. Japan Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Test Type
    - 8.3.3.2.2. By End User
- 8.3.4. South Korea Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Test Type
    - 8.3.4.2.2. By End User
- 8.3.5. Australia Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Test Type
    - 8.3.5.2.2. By End User

9. Middle East & Africa Rheumatoid Arthritis Diagnostic Tests Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Test Type
- 9.2.2. By End User
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Test Type
    - 9.3.1.2.2. By End User
- 9.3.2. UAE Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Test Type
    - 9.3.2.2.2. By End User
- 9.3.3. South Africa Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Test Type
    - 9.3.3.2.2. By End User

10. South America Rheumatoid Arthritis Diagnostic Tests Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Test Type
- 10.2.2. By End User
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Test Type
    - 10.3.1.2.2. By End User
- 10.3.2. Colombia Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Test Type
    - 10.3.2.2.2. By End User
- 10.3.3. Argentina Rheumatoid Arthritis Diagnostic Tests Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Test Type
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Rheumatoid Arthritis Diagnostic Tests Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Abbott Laboratories Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Siemens Healthineers AG
15.3. Thermo Fisher Scientific Inc.
15.4. Exagen Inc.
15.5. Augurex Life Sciences Corp.
15.6. Danaher Corporation
15.7. Bio-Rad Laboratories, Inc.
15.8. Tulip Diagnostics (P) Ltd
15.9. Boditech Med Inc.
15.10. Getein Biotech, Inc.